U.S. patent application number 13/175659 was filed with the patent office on 2012-01-05 for capillary perfused bioreactors with multiple chambers.
This patent application is currently assigned to VANDERBILT UNIVERSITY. Invention is credited to Franz J. Baudenbacher, Chang Y. Chung, David Cliffel, Frederick R. Haselton, William H. Hofmeister, Eugene J. Leboeuf, Charles P. Lin, Lisa J. McCawley, Ales Prokop, Randall S. Reiserer, Mark A. Stremler, John P. Wikswo.
Application Number | 20120003729 13/175659 |
Document ID | / |
Family ID | 36612175 |
Filed Date | 2012-01-05 |
United States Patent
Application |
20120003729 |
Kind Code |
A1 |
Wikswo; John P. ; et
al. |
January 5, 2012 |
CAPILLARY PERFUSED BIOREACTORS WITH MULTIPLE CHAMBERS
Abstract
A bioreactor for cultivating living cells in a liquid medium. In
one embodiment of the present invention, the bioreactor includes a
first substrate having a first surface, an opposite second surface
and edges. The bioreactor further includes a second substrate
having a first surface and an opposite second surface, defining a
cavity with a bottom surface, where the bottom surface is located
therebetween the first surface and the second surface. The first
surface of the first substrate is received by the second surface of
the second substrate to cover the cavity so as to form a channel
for receiving cells and a liquid medium. In forming the bioreactor,
the channel is sized to allow the growth of a layer of cells on a
biocompatible coating layer and a flow of liquid in the channel.
The flow of liquid is controlled so as to provide a known shear
force to the layer of cells. The flow of liquid can be further
controlled so as to provide an environment that simulates a
vascular space in the channel.
Inventors: |
Wikswo; John P.; (Brentwood,
TN) ; Baudenbacher; Franz J.; (Franklin, TN) ;
Prokop; Ales; (Franklin, TN) ; Leboeuf; Eugene
J.; (Franklin, TN) ; Chung; Chang Y.;
(Franklin, TN) ; Cliffel; David; (Nashville,
TN) ; Haselton; Frederick R.; (Nashville, TN)
; Hofmeister; William H.; (Nashville, TN) ; Lin;
Charles P.; (Brentwood, TN) ; McCawley; Lisa J.;
(Nashville, TN) ; Reiserer; Randall S.;
(Nashville, TN) ; Stremler; Mark A.; (Franklin,
TN) |
Assignee: |
VANDERBILT UNIVERSITY
Nashville
TN
|
Family ID: |
36612175 |
Appl. No.: |
13/175659 |
Filed: |
July 1, 2011 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12398825 |
Mar 5, 2009 |
8003378 |
|
|
13175659 |
|
|
|
|
10525559 |
Oct 24, 2005 |
7534601 |
|
|
12398825 |
|
|
|
|
Current U.S.
Class: |
435/288.7 ;
435/287.1; 435/289.1; 435/297.1 |
Current CPC
Class: |
B01L 2400/0487 20130101;
C12M 29/10 20130101; B01L 2200/0668 20130101; C12M 23/16 20130101;
B01L 3/502761 20130101; B01L 2300/0877 20130101; B01L 2400/0406
20130101; B01L 2300/0816 20130101; B01L 2400/0415 20130101; B01L
2300/0864 20130101; B01L 3/502746 20130101; B01L 2300/10
20130101 |
Class at
Publication: |
435/288.7 ;
435/289.1; 435/297.1; 435/287.1 |
International
Class: |
C12M 1/34 20060101
C12M001/34; C12M 1/12 20060101 C12M001/12; C12M 1/04 20060101
C12M001/04; C12M 1/00 20060101 C12M001/00 |
Goverment Interests
STATEMENT OF FEDERALLY-SPONSORED RESEARCH
[0002] The invention was made with Government support under Grant
No. N66001-01-C-8064 awarded by the Defense Advanced Research
Projects Administration and the Office of Naval Research. The
invention was also made with Government support under Grant No.
5R43RR016124-02 awarded by the National Institute of Health. The
government has certain rights in the invention.
Claims
1-27. (canceled)
28. A bioreactor comprising: (i) a first substrate having a first
surface and an opposite second surface, defining a chamber
therebetween for receiving biological cells and a liquid medium;
(ii) an inlet port formed in the first substrate; (iii) a first
connection channel formed in the first substrate, wherein the first
connection channel is in fluid communication with the inlet port
and the chamber for allowing a stream of substance to be delivered
to the chamber; (iv) an outlet port formed in the first substrate;
(v) a second connection channel formed in the first substrate,
wherein the second connection channel is in fluid communication
with the outlet port and the chamber for allowing a stream of
substance to be removed from the chamber; and (vi) confining means
positioned in a region in the chamber proximate to the first
connection channel to confine the biological cells.
29. The bioreactor of claim 28, wherein the confining means
comprises a plurality of traps, wherein each of the plurality of
traps is capable of receiving at least one biological cell.
30. The bioreactor of claim 29, wherein each of the plurality of
traps comprises a structure defining a recess so as to receive and
confine at least one biological cell therein.
31. The bioreactor of claim 30, wherein the structure is partially
formed with a filter to allow the recess to be in fluid
communication with the chamber.
32. The bioreactor of claim 29, wherein the plurality of traps
forms an array.
33. The bioreactor of claim 28, wherein the first substrate further
defines a first alternate port and a third connection channel in
fluid communication with the first alternate port and the first
connection channel for allowing additional substance to be
introduced into the chamber.
34. The bioreactor of claim 28, wherein the first substrate further
defines a second alternate port, a third connection channel, and a
second chamber, wherein the third connection channel is in fluid
communication with second alternate port and the second chamber,
and the second chamber is in fluid communication with the first
connection channel.
35. The bioreactor of claim 34, wherein the second chamber is
formed with an oxygen permeable structure to provide oxygen to the
biological cells.
36. The bioreactor of claim 28, wherein the first substrate is
fabricated from glass, Mylar, PDMS, silicon, a polymer, a
semiconductor, or any combination of them.
37. The bioreactor of claim 28, further comprising a second
substrate having a first surface and an opposite, second surface,
and means adapted for electrochemical measurements of the
biological cells in the chamber, wherein the means for
electrochemical measurements is positioned with the second
substrate such that when the first surface of the second substrate
is received by the second surface of the first substrate, the means
for electrochemical measurements is at a corresponding measurement
position.
38. The bioreactor of claim 37, wherein the means for
electrochemical measurements comprises: at least one electrode
monitoring entry of the biological cells into the chamber; at least
one electrode monitoring leaving of the biological cells from the
chamber; and a plurality of electrodes detecting chemical species
in the chamber.
39. The bioreactor of claim 28, further comprising a third
substrate having a first surface and an opposite, second surface,
and means adapted for optical measurements, wherein the means for
optical measurements is positioned with the third substrate such
that when the first surface of the third substrate is received by
the second surface of the first substrate, the means for optical
measurements is at a corresponding measurement position.
40. The bioreactor of claim 39, wherein the means for optical
measurements comprises a plurality of optical sensors strategically
positioned for detecting chemical and biological species within the
chamber and the physiological state of the biological cells within
the chamber.
41. The bioreactor of claim 39, wherein the third substrate is at
least partially transparent.
42-49. (canceled)
50. A bioreactor comprising: (i) a first substrate having a first
surface and an opposite second surface, defining a first chamber
therebetween for receiving a first type of biological cells and a
liquid medium; (ii) at least one second chamber formed in the first
substrate for receiving a second type of biological cells and a
liquid medium; and (iii) at least one connection channel formed in
the first substrate, wherein at least one connection channel is in
fluid communication with a corresponding second chamber and the
first chamber for allowing the first type of biological cells and
the second type of the biological cells to interact with each
other.
51. The bioreactor of claim 50, wherein the first type of
biological cells comprises protozoa, and the second type of
biological cells comprises bacteria.
52. (canceled)
53. The bioreactor of claim 51, wherein the connection channel is
formed to allow protozoa to travel therein, and further comprising
a sizing limiting post to limit the mobility of protozoa.
Description
CROSS-REFERENCE TO RELATED PATENT APPLICATION
[0001] This application is a divisional of, and claims benefit of
U.S. patent application Ser. No. 12/398,825, filed Mar. 5, 2009,
entitled "Capillary Perfused Bioreactors with Multiple Chambers,"
by John P. Wikswo, which status is allowed, and which itself is a
divisional application of, and claims benefit of U.S. patent
application Ser. No. 10/525,559, filed Oct. 24, 2005, entitled
"Capillary Perfused Bioreactors with Multiple Chambers," by John P.
Wikswo, et al., now U.S. Pat. No. 7,534,601, which itself claims
benefit of Application No. PCT/US03/26801 filed Aug. 27, 2003,
which itself claims priority to U.S. Provisional Patent Application
Ser. No. 60/406,278, filed Aug. 27, 2002, the disclosures of each
of which are hereby incorporated by reference herein in their
entireties.
[0003] Some references, which may include patents, patent
applications and various publications, are cited in a reference
list and discussed in the description of this invention. The
citation and/or discussion of such references is provided merely to
clarify the description of the present invention and is not an
admission that any such reference is "prior art" to the invention
described herein. In terms of notation, hereinafter, "[n]"
represents the nth reference cited in the reference list. For
example, [.sup.1] represents the 11th reference cited in the
reference list, namely, Hu, W. S. and Aunins, J. G., Large-Scale
Mammalian Cell Culture, Curr. Opin. Biotechnol., 8, 148-153,
1997.
FIELD OF THE INVENTION
[0004] The present invention generally relates to an apparatus and
methods for growing and maintaining a living system. More
particularly, the present invention relates to an apparatus and
methods that have a channel configuration allowing perfusate flow
with diffusional exchange to tissue cells but no cell migration.
Additionally, the present invention relates to an apparatus and
methods that have capacity for growing and maintaining a living
microorganism such as protozoa. The present invention also relates
to an apparatus and methods for dynamic analysis of a collection of
cells such as a biofilm. More particularly, the present invention
relates to an apparatus and methods for measuring response of a
biofilm to one or more dynamic streams of substance such as
chemical stressors at various depths of the biofilm.
[0005] Certain embodiments of the present invention comprise
apparatus and methods for growing and maintaining a living system
such as a cell or a collection of cells and monitoring the status
of such a living system that is metabolically active and responsive
to environmental change, wherein each metabolic activity of the
cell may be characterized by a characteristic time. More
particularly, the apparatus and methods comprise bioreactors with
multiple chambers and methods of using the same.
[0006] Certain other embodiments of the present invention comprise
apparatus and methods for growing and maintaining a living system
such as a cell or a collection of cells and monitoring the status
of such a living system that is metabolically active and responsive
to environmental change, wherein each metabolic activity of the
cell may be characterized by a characteristic time. More
particularly, the apparatus and methods comprise bioreactors with
an array of chambers with a common feed line and methods of using
the same.
[0007] Certain additional embodiments of the present invention
comprise apparatus and methods for growing and maintaining a living
system such as a cell or a collection of cells and monitoring the
status of such a living system that is metabolically active and
responsive to environmental change, wherein each metabolic activity
of the cell maybe characterized by a characteristic time. More
particularly, the apparatus and methods comprise capillary perfused
bioreactors and methods of using the same.
[0008] Certain further embodiments of the present invention
comprise apparatus and methods for growing and maintaining a living
system such as a cell or a collection of cells and monitoring the
status of such a living system that is metabolically active and
responsive to environmental change, wherein each metabolic activity
of the cell may be characterized by a characteristic time. More
particularly, the apparatus and methods comprise bioreactors with
substance injection capability and methods of using the same.
BACKGROUND OF THE INVENTION
[0009] Bioreactor is a device that can be used for culturing living
cells. More particularly, bioreactors are vessels that provide a
proper physical and chemical environment as well as fast transport
of substrates and products to allow cellular biological reactions
to occur, ideally rapidly and efficiently. The simplest bioreactor
is a culture dish: In conventional cell culture using well-plates,
culture-dishes, and flasks, the volume of the culture medium is
typically 200 to 1000 times the volume of the cells. This ratio,
when used in combination with buffering of the culture media,
allows the cells to grow for at least 24 hours without media
change. However, another consequence of this ratio is a
corresponding dilution of whatever extracellular factors are
produced by the cells and might otherwise provide paracrine
cell-to-cell communication, which is possible in tissue because the
extracellular volume might be only 10% of intracellular volume.
[0010] Much of the development of bioreactors was directed towards
either the functional tissues, or the generation of biochemicals
and pharmaceuticals. For example, over the last 20 years studies on
the generation of skin, pancreas, cartilage, liver, cornea and
bladder have taken particular importance.sup.1. In the United
States alone, there are more than 80,000 individuals waiting for an
organ transplant, and hence the need to develop improved bioreactor
technology is self-evident. There is also a growing recognition
that progress in understanding cell motility and chemotactic
signaling, as well as other complex cellular processes, is often
constrained by the laboratory techniques available for observing
and intervening at various points in the processes. Many of these
processes can be examined best in a properly instrumented
bioreactor.
[0011] There is a wide variety in bioreactors, including stirred
vessels, bubble column, packed beds.sup.2, air-lift reactors, and
membrane reactors.sup.3 that include plates, rotating plates,
spiral-wound and hollow fibres. Hollow-fiber reactors are of
special importance since (depending of their structure) they may
allow as much as 30,000 m.sup.2 of membrane area per m.sup.3 module
volume.sup.4-6. However, given that mammalian cells are very
sensitive to shear forces.sup.7-9 (which originate mainly from
agitation and aeration), it is important to reduce the forces as
much as possible in the reactor where the cells will be
grown.sup.9,10. Membranes have been used in bioreactors to increase
survival of cells. For instance, it has been known that liquid-gas
interface created in some models of reactors is particularly
damaging for mammalian cells. That potentially lethal interface can
be eliminated by the use of a hydrophobic membrane.sup.9.
[0012] Bioreactors may be also classified by means of their mode of
operation: batch, fed-batch and continuous cultivation (also called
perfused cultivation), the first or batch mode, no substrate is
added, nor medium removed; in the case of the fed-batch mode there
is a continuous feeding, but nothing is removed until the reactions
are terminated and the reactor emptied. While these systems imply a
low effort for process control, the productivity is low compared to
that in perfused systems, the third mode, where a permanent inflow
of substrate and outflow of medium takes place. Besides the high
productivity, there is a better cell physiology control in this
kind of reactors.sup.11 and in the case of mammalian cell culture,
it has been shown to provide significant advantage over static
methods.sup.12,13.
[0013] One of the limitations when developing large
three-dimensional tissues is the lack of a proper vascular supply
for nutrient and metabolite transport. A number of studies have
analyzed the artificial vascular networks.sup.14-18, and there have
been a number of attempts to construct functional microfabricated
scaffolds.sup.3,6,19-21. The techniques by which these networks
have been produced include plasma etching, photolithography, soft
lithography, microcontact printing, microfluidic patterning using
microchannels, laminar flow patterning and stencil
patterning.sup.22-25. In the case of plasma etching technologies we
can consider the high aspect ratio micromachining (HARMS) as a very
powerful tool since it allows to etch channels of virtually
unlimited depth without increasing the width already achieved by
lithography.sup.22. It is also possible to construct three
dimensional microchannel systems in PDMS with complex topologies
and geometries.sup.15.
[0014] Additionally, one needs to realize that the growth of
clinically-implantable tissue may require the ultimate
biodegradation and the mechanical properties of the tissue
scaffold.sup.16. These properties are directly related to the
crystallimty, molecular weight, glass transition temperature and
monomer hydrophobicity of the materials chosen to fabricate the
tissue.sup.19. Naturally derived materials such as collagen have
been employed.sup.26, as well as synthetic and semi synthetic ones.
Polyglycolic acid (PGA) possesses high porosity and it makes easy
the fabrication of devices, therefore, PGA fibre meshes have been
considered to transplant cells. However, they cannot resist
significant compressional forces. An alternative to solve this
problem is to use polymers of lactic and glycolic acid whose ratios
can be adjusted to control the crystallinity of the material and
hence the degradation rate and mechanical properties. Fibre-based
tubes have been fabricated from these polymers.sup.27.
[0015] It is important to compare the vascular nature of living
tissue with the capabilities provided by existing microfabricated
cell-perfusion bioreactor systems. In tissue, arteries divide into
progressively smaller vessels, eventually reaching arterioles and
then capillaries. The arterioles are important because they contain
the precapillary sphincters, which allow control of the perfusion
of individual capillary beds, but also provide the majority of the
peripheral resistance and hence the pressure drop associated with
the arterial supply. As a result, the pressure difference across
the capillary endothelium membrane is kept sufficiently low to
allow diffusional transport of nutrients and metabolites across the
membrane, as well as the trafficking of immune cells required for
tissue maintenance and infection control. Were the pressures in the
capillaries as high as those in the arterioles, the capillary wall
thickness would be too great to allow these critical transport
phenomena. The venous return system is in many ways a mirror of the
arterial system, albeit at lower pressures. Another feature of the
living vascular system is that the branching process described
above allows all cells to be within 50 to 200 microns of a
capillary, depending upon the specific tissue. As a result, the
arterial supply and venous return systems are intercalated in such
a manner that every capillary that perfuses a large group of cells
is connected to the larger supply and return systems with a
self-similarity that ensures uniform perfusion and transcapillary
pressures. It is this intercalation process that is so difficult to
replicate with microfabrication. For example, Borenstein et
al.,.sup.22 describe a process to build a two-dimensional vascular
system that could create a multi-scale perfusion system for
supporting endothelial cells, but there is no provision to
selectively limit diffusive transport across the smallest
capillaries to perfuse cells lying outside of the perfusion
network. More importantly, the networks they show have a large
region of the device that is covered with the larger vessels, and
the region of the bioreactor that is limited to capillary vessels
is in fact quite small.
[0016] Thus, there is a need for microfabricated migration
bioreactors that mimic in vitro the microenvironments of normal
tissue was well as that of tumors, infected tissue, and wounded
tissue, while providing independent control of chemokine and growth
factor gradients, shear forces, cellular perfusion, and the
permeability of physical barriers to cellular migration, thereby
allowing detailed optical and electrochemical observation of
normal, immune, and cancerous cells during cell migration,
intravasation, extravasation, and angiogenesis. Angiogenesis, tumor
metastasis, and leukocyte infiltration into tissue are complex
processes that are regulated not only by cellular responses to a
single chemokine, but also by external factors, such as multiple
competing chemokine and growth factor signals, autocrine feedback
loops, cell-cell interactions, and mechanical forces such as vessel
shear stress. Current approaches for assessing migration across
cellular barriers include Boyden and transwell chambers that
provide an integrated fluorescence assay of migration across
filters to allow quantitation of migration.sup.28-34, parallel
plate flow chambers.sup.35-38, in which adhesion and rolling on
endothelial cells in shear stress can be assessed.sup.35,39-44, and
in vivo intravital microscopy in which migration of cells in living
animals is visualized.sup.45-48. Each of these approaches has
limitations, including the inability to have sustained and
controlled chemotactic gradients (all systems), the inability to
visualize migration in real time or with physiologic shear stress
(Boyden and transwell chambers), the inability to observe
extravasation or angiogenesis into an underlying, deep cellular
matrix (parallel plate flow chambers) and the inability to control
all aspects of the experiments, e.g., having defined cell
populations and controlled microfluidics for independent control of
shear and tissue perfusion (all systems, especially intravital
microscopy). The development of a motility/metastasis model system
with independent control of endothelial shear stress, chemokine
gradients, tissue perfusion, and the ability to add different cell
types through different ports, combined with state-of the art
imaging techniques and sensor capabilities would represent a huge
advance over currently available systems.
[0017] Indeed, the need for such capabilities is quite urgent.
Angiogenesis is a dynamic process, influenced by the cellular
microenvironment and intricately linked to metastasis.sup.49,50. It
has been demonstrated that both VEGF and angiopoietin/tyrosine
kinase (Ang/Tie2) function are required for tumor
angiogenesis.sup.51-53. However, how signals from those two
receptor systems are integrated to mediate angiogenesis has not
been determined, in part due to the lack of good model systems. The
next step would be to study the coordination and integration of
VEGF and Ang signaling in endothelial cell migration, vascular
sprouting and maturation, and tumor transendothelium migration. As
with angiogenesis, multiple environmental inputs affect tumor
metastasis and leukocyte infiltration. Activation of one chemokine
receptor in tumor cells affects the induction of other ligands and
receptors in tumor cells as well as endothelial cells and
leukocytes, but the mechanism is poorly understood.sup.54. There is
a need for an understanding of how alteration of chemokine receptor
internalization and/or changes in receptor association with adaptor
molecules such as AP-2 or beta-arresting affect chemokine receptor
activity as tumor cells move through a complex matrix. How external
factors such as cell-cell adhesion, cell-matrix interactions, and
vessel shear stress affect cytoskeletal reorganization during
migration through tissues is also poorly understood. Cortactin
overexpression increases the metastasis of breast cancer cells to
bone.sup.55, however the mechanism remains unclear. Likewise, lack
of WASp protein in humans leads to an X-linked immune disorder that
may result from signaling, proliferation or chemotaxis
defects.sup.56. There is a need to study the role of cortactin and
WASp proteins in chemotaxis of breast cancer and HL60 cells in a
complex multicell environment involving controllable shear,
cell-cell interactions, and chemokine gradients. As a final
example, matrix metalloproteinases (MMPs) are extracellularly
expressed enzymes found in many types of cancer and are thought to
be important in tumor development, growth, invasion and metastasis.
It has recently been discovered that skin tumors that develop in
mice deficient for MMP-3 (MMP-3 null mice) progress and grow much
faster than skin tumors from normal, wild-type mice. This
difference is associated with a reduced number of immune cells in
the tumor and surrounding tissue in the MMP-3 null mice. The
logical progression of this research is to determine how loss of an
MMP affects the ability of immune cells, namely monocytes and
neutrophils, to infiltrate from the peripheral blood circulation to
the tumor site. The ability to control the experimental
environment, including multiple defined cell populations, is
critical to elucidate the relative importance of tumor-host
interactions in MMP-3 induced cellular chemotaxis.
[0018] Despite the progress made over the years, however, currently
available bioreactors cannot provide a more physiologic environment
that would include a three-dimensional in vitro region with
multiple cell types, stimuli, and measurement capabilities and
allows study of molecular aspects of the chemotactic response.
Thus, bioreactors that mimic in vitro the microenvironments of
tumors and tissue while providing independent control of chemokine
and growth factor gradients, shear forces, cellular perfusion, and
the permeability of physical barriers to cellular migration,
thereby allowing detailed optical and electrochemical observation
of normal and cancerous cells during cell migration, intravasation,
extravasation, and angiogenesis need to be developed.
[0019] Therefore, a heretofore unaddressed need exists in the art
to address the aforementioned deficiencies and inadequacies.
SUMMARY OF THE INVENTION
[0020] In one aspect, the present invention relates to a bioreactor
for cultivating living cells in a liquid medium. In one embodiment,
the bioreactor includes a first substrate having a first surface,
an opposite second surface and edges. The bioreactor further
includes a second substrate having a first surface and an opposite
second surface, defining a cavity with a bottom surface, where the
bottom surface is located therebetween the first surface and the
second surface. The first surface of the first substrate is
received by the second surface of the second substrate to cover the
cavity so as to form a channel for receiving cells and a liquid
medium. The second substrate can be fabricated from glass, Mylar,
PDMS, silicon, a polymer, a semiconductor, or any combination of
them. The first substrate is at least partially optically
transparent such that the dynamic activities of cells in the
channel are detectable through optical detecting means.
[0021] A recess is formed in the second substrate with a bottom
surface and in fluid communication with the channel. Additionally,
a barrier is positioned for covering the recess so as to form an
outer chamber. The barrier has a porosity to allow the channel and
the outer chamber to be in fluid communication and control the move
of at least one predetermined type of cells between the channel and
the outer chamber. In one embodiment, the barrier includes a
plurality of posts spaced with a gap from each other. These posts
may be coated in certain locations with substances to prevent entry
of cells, particularly the endothelial cells. Gaps between the
posts in certain locations allow for delivery of particular cell
types to the outer chamber.
[0022] The second substrate further defines a first opening and an
opposite, second opening adapted for allowing a flow of liquid to
be introduced into the channel through the first opening and away
from the channel through the second opening substantially along a
first direction.
[0023] The bioreactor further includes a biocompatible coating
layer applied to the interior surfaces of the second substrate
around the channel. The biocompatible coating layer includes a
material that may inhibit cell adhesion to the biocompatible
coating layer, enhance cell adhesion to the biocompatible coating
layer, promote organization and growth of cells, or function as a
fluorescent marker or indicator of the state of cells. In forming
the bioreactor, the channel is sized to allow the growth of a layer
of cells on the biocompatible coating layer and the flow of liquid
in the channel. The flow of liquid is controlled so as to provide a
known shear force to the layer of cells. The flow of liquid can be
further controlled so as to provide an environment that simulates a
vascular space in the channel.
[0024] The cells can be any type of living cells, including, but
not limited to, bacteria, protozoa, or both, normal cells,
endothelial cells, tumor cells, or any combination of them. Cells
can be introduced into the channel individually, in a collection of
cells, or in the form of biofilm. In one embodiment, the layer of
cells substantially forms an endothelial cell-lined capillary in
the channel. The channel is sized such that when at least one cell
that is not one of the endothelial cells, such as a tumor cell, is
introduced into the channel, it can undergo intravasation in the
endothelial cell-lined capillary.
[0025] The second substrate further defines one or more injection
ports, in fluid communication with the chamiel to allow a stream of
substance to be introduced into the channel through the injection
port, substantially along a second direction, respectively. The
second direction is substantially perpendicular to the first
direction. The stream of substance is controlled so as to provide a
gradient to the channel. The stream of substance includes a
substance affecting the growth of cells such as chemokine.
[0026] The outer chamber is sized to allow the growth of a host of
cells. The host of cells includes at least a first type of cells
and a second type of cells that is different from the first type of
cells. In other words, the outer chamber is sized to allow the
growth of two types of cells. In one embodiment, the first type of
cells includes normal cells, and the second type of cells includes
rumor cells. A port and a connection channel are formed in the
second substrate such that the connection channel is in fluid
communication with the outer chamber and the port. The bioreactor
further includes a plurality of electrodes adapted for
electrochemical measurements of the host of cells. Moreover, the
bioreactor further includes a plurality of controlling ports, and a
plurality of connection channels, wherein each of the connection
channels is in fluid communication with a corresponding one of
controlling port, and the outer chamber, respectively.
[0027] The bioreactor can be used as a capillary perfused migration
bioreactor for the study of cancer cells or neutrophil
extravasation in the presence of two competing chemokine gradients.
In particular, a first stream of chemokine is injected through a
port and hence creates a first gradient of that chemokine both in
the outer chamber and the channel. Additionally, a second stream of
chemokine is injected through a port and hence creates a second
gradient of that chemokine both in the outer chamber and the
channel.
[0028] In another aspect, the present invention relates to another
type of bioreactor and its variants for cultivating living cells in
a liquid medium. In one embodiment, the bioreactor includes a first
substrate having a first surface and an opposite second surface,
defining a chamber therebetween for receiving cells and a liquid
medium. The first substrate can be fabricated from glass, Mylar,
PDMS, silicon, a polymer, a semiconductor, or any combination of
them.
[0029] An inlet port and a first connection channel are formed in
the first substrate, where the first connection channel is in fluid
communication with the inlet port and the chamber for allowing a
stream of substance to be delivered to the chamber. Additionally,
an outlet port and a second connection channel are formed in the
first substrate, where the second connection channel is in fluid
communication with the outlet port and the chamber for allowing a
stream of substance to be removed from the chamber.
[0030] Moreover, the bioreactor has confining means positioned in a
region in the chamber proximate to the first connection channel to
confine the cells. In one embodiment, the confining means includes
a plurality of traps, where each of the plurality of traps is
capable of receiving at least one cell or a collection of cells.
Each of the plurality of traps includes a structure defining a
recess so as to receive and confine one or more cells therein. The
structure may be partially formed with a filter to allow the recess
to be in fluid communication with the chamber. The filter can be
formed with a plurality of posts spacing from each other with a gap
g. Traps can take various shapes and have different physics
properties. The plurality of traps can be arranged to form an
array.
[0031] Additionally, the first substrate defines a first alternate
port and a third connection channel in fluid communication with the
first alternate port and the first connection channel for allowing
additional substance to be introduced into the chamber. Moreover,
the first substrate further defines a second alternate port, a
third connection channel, and a second chamber, wherein the third
connection channel is in fluid communication with second alternate
port and the second chamber, and the second chamber is in fluid
communication with the first connection channel. Furthermore, the
second chamber is formed with an oxygen permeable structure to
provide oxygen to the cells.
[0032] The bioreactor further includes a second substrate having a
first surface and an opposite, second surface, and means adapted
for electrochemical measurements of the cells in the chamber. The
means for electrochemical measurements is positioned with the
second substrate such that when the first surface of the second
substrate is received by the second surface of the first substrate,
the means for electrochemical measurements is at a corresponding
measurement position. The means for electrochemical measurements
includes at least one electrode monitoring entry of the cells into
the chamber, at least one electrode monitoring leaving of the cells
from the chamber, and a plurality of electrodes detecting chemical
species in the chamber.
[0033] The bioreactor further includes a third substrate having a
first surface and an opposite, second surface, and means adapted
for optical measurements. The means for optical measurements is
positioned with the third substrate such that when the first
surface of the third substrate is received by the second surface of
the first substrate, the means for optical measurements is at a
corresponding measurement position. The means for optical
measurements includes a plurality of optical sensors strategically
positioned for detecting chemical and biological species within the
chamber and the physiological state of the cells within the
chamber. The third substrate is at least partially transparent.
[0034] In yet another aspect, the present invention relates to an
inventive bioreactor and its variants. In one embodiment, the
bioreactor includes a first substrate having a first surface and an
opposite second surface, defining a chamber therebetween for
receiving cells and a liquid medium. The first substrate can be
fabricated from glass, Mylar, PDMS, silicon, a polymer, a
semiconductor, or any combination of them. The bioreactor further
includes a second substrate sized such that when the second
substrate is received by the first substrate, the chamber is
covered.
[0035] An inlet port and a first connection channel are formed in
the first substrate, where the first connection channel is in fluid
communication with the inlet port and the chamber for allowing a
stream of substance to be delivered to the chamber.
[0036] Additionally, an outlet port and a second connection channel
are formed in the first substrate, where the second connection
channel is in fluid communication with the outlet port and the
chamber for allowing a stream of substance to be removed from the
chamber.
[0037] The bioreactor further has confining means positioned in the
chamber to form a confinement region to confine the cells therein.
In one embodiment, the confining means includes a first filter and
a second filter, where the first filter is positioned proximate to
the first connection channel and the second filter is positioned
proximate to the second connection channel, and the first filter
and the second filter are substantially parallel to each other.
Each of the first filter and the second filter includes a plurality
of posts spaced apart from each other not to allow cells to pass
through it. The distances between two neighboring posts can
vary.
[0038] The first substrate, further defines a first alternate port
and a third connection channel that is in fluid communication with
the first alternate port and the confined region of the chamber for
allowing seed cells to perfuse only outside the confined region in
the chamber.
[0039] The bioreactor further includes one or more supporting
members positioned outside the confined region of the chamber for
supporting the second substrate. Additionally, the bioreactor
further includes at least one supporting member positioned inside
the confined region of the chamber for supporting the second
substrate. Note that the chamber is formed with sidewalls of the
chamber are tapered at the intersections of the connection channels
with the chamber to form an angle of inclination .alpha., which is
preferred in the range of about between 10-45.degree. from
vertical, and an enclosed angle .beta., which is preferred in the
range of about between 30-80.degree., respectively, to reduce shear
forces generated by sharp corners.
[0040] In a further aspect, the present invention relates to
another inventive bioreactor and its variants. In one embodiment,
the bioreactor includes a first substrate having a first surface
and an opposite second surface, defining a first chamber
therebetween for receiving a first type of cells and a liquid
medium. One or more second chambers are formed in the first
substrate for receiving a second type of cells and a liquid medium.
Moreover, one or more connection channels are formed in the first
substrate, wherein each of connection channels is in fluid
communication with a corresponding second chamber and the first
chamber for allowing the first type of cells and the second type of
the cells to interact with each other. For example, connection
channel is in fluid communication with a corresponding second
chamber and the first chamber. The first type of cells includes
protozoa, and the second type of cells includes bacteria.
[0041] The connection channels are formed to allow protozoa to
travel therein. However, a variety of structures can be utilized to
limit the mobility of protozoa for different applications. For
example, a size limiting or exclusion post can be utilized to limit
the mobility of protozoa, which can be used to evaluate the
mobility of protozoa. Alternatively, one of the connection channels
formed with a cross-sectional dimension variable along the length
of the connection channel can be utilized to limit the mobility of
protozoa, which can also be used to evaluate the mobility of
protozoa. Moreover, a barrier positioned in a connection channel
can be utilized for separation of bacteria and protozoa, which can
be used to evaluate protozoa chemotaxis.
[0042] These and other aspects of the present invention will become
apparent from the following description of the preferred embodiment
taken in conjunction with the following drawings, although
variations and modifications therein may be affected without
departing from the spirit and scope of the novel concepts of the
disclosure.
BRIEF DESCRIPTION OF THE DRAWINGS
[0043] FIGS. 1A1-3 schematically show a bioreactor according to one
embodiment of the present invention: 1A1, a top cross-sectional
view; 1 A2, a transverse cross-sectional view; and 1A3, a lateral
cross-sectional view.
[0044] FIG. 1B schematically shows a top cross-sectional view of a
bioreactor according to another embodiment of the present
invention.
[0045] FIG. 1C schematically shows a top cross-sectional view of a
bioreactor according to yet another embodiment of the present
invention.
[0046] FIG. 1D schematically shows a top cross-sectional view of a
bioreactor according to a further embodiment of the present
invention.
[0047] FIGS. 2A1-2 schematically show a bioreactor with multiple
traps according to one embodiment of the present invention: 2A1, a
perspective view; and 2A2, a perspective sectional view.
[0048] FIG. 2B schematically shows a perspective view of a
bioreactor with multiple traps according to another embodiment of
the present invention.
[0049] FIG. 2C schematically shows a top cross-sectional view of a
bioreactor with a confined region according to one embodiment of
the present invention.
[0050] FIG. 2D schematically shows a top cross-sectional view of a
bioreactor with a confined region according to another embodiment
of the present invention.
[0051] FIG. 2E schematically shows a top cross-sectional view of a
bioreactor with a confined region according to yet another
embodiment of the present invention.
[0052] FIG. 2F schematically shows a top cross-sectional view of a
bioreactor with a confined region according to a further embodiment
of the present invention.
[0053] FIG. 2G schematically shows a top cross-sectional view of a
bioreactor with multiple traps according to one embodiment of the
present invention.
[0054] FIG. 2H schematically shows a top cross-sectional view of a
bioreactor with multiple traps according to another embodiment of
the present invention
[0055] FIG. 2I schematically shows a top cross-sectional view of a
bioreactor with multiple traps according to yet another embodiment
of the present invention.
[0056] FIGS. 3A-D schematically show a top cross-sectional view of
a bioreactor with a multi-chamber according to one embodiment of
the present invention.
DETAILED DESCRIPTION OF THE INVENTION
[0057] Various embodiments of the invention are now described in
detail. Referring to the drawings, like numbers indicate like parts
throughout the views unless the context clearly dictates otherwise.
As used in the description herein and throughout the claims that
follow, the meaning of "a," "an," and "the" includes plural
reference unless the context clearly dictates otherwise. Also, as
used in the description herein and throughout the claims that
follow, the meaning of "in" includes "in" and "on" unless the
context clearly dictates otherwise. Additionally, some terms used
in this specification are more specifically defined below.
DEFINITIONS
[0058] The terms used in this specification generally have their
ordinary meanings in the art, within the context of the invention,
and in the specific context where each term is used. For example,
conventional techniques of molecular biology, microbiology and
recombinant DNA techniques may be employed in accordance with the
present invention. Such techniques and the meanings of terms
associated therewith are explained fully in the literature. See,
for example, Sambrook, Fitsch & Maniatis. Molecular Cloning: A
Laboratory Manual, Second Edition (1989) Cold Spring Harbor
Laboratory Press, Cold Spring Harbor. New York (referred to herein
as "Sambrook et al., 1989"); DNA Cloning: A Practical Approach,
Volumes I and II (D. N. Glover ed. 1985); Oligonucleotide Synthesis
(M. J. Gait ed. 1984); Nucleic Acid Hybridization (B. D. Hames
& S. J. Higgins, eds. 1984); Animal Cell Culture (R. I.
Freshney, ed. 1986); Immobilized Cells and Enzymes (IRL Press,
1986); B. E. Perbal, A Practical Guide to Molecular Cloning (1984);
F. M. Ausubel et al. (eds.), Current Protocols in Molecular
Biology, John Wiley & Sons, Inc. (1994). See also, PCR
Protocols: A Guide to Methods and Applications, Innis et al., eds.,
Academic Press, Inc., New York (1990); Saiki et al., Science 1988,
239:487; and PCR Technology: Principles and Applications for DNA
Amplification, H. Erlich, Ed., Stockton Press.
[0059] Certain terms that are used to describe the invention are
discussed below, or elsewhere in the specification, to provide
additional guidance to the practitioner in describing the devices
and methods of the invention and how to make and use them. For
convenience, certain terms are highlighted, for example using
italics and/or quotation marks. The use of highlighting has no
influence on the scope and meaning of a term; the scope and meaning
of a term is the same, in the same context, whether or not it is
highlighted. It will be appreciated that the same thing can be said
in more than one way. Consequently, alternative language and
synonyms may be used for any one or more of the terms discussed
herein, nor is any special significance to be placed upon whether
or not a term is elaborated or discussed herein. Synonyms for
certain terms are provided. A recital of one or more synonyms does
not exclude the use of other synonyms. The use of examples anywhere
in this specification, including examples of any terms discussed
herein, is illustrative only, and in no way limits the scope and
meaning of the invention or of any exemplified term. Likewise, the
invention is not limited to various embodiments given in this
specification.
[0060] As used herein, "about" or "approximately" shall generally
mean within 20 percent, preferably within 10 percent, and more
preferably within 5 percent of a given value or range. Numerical
quantities given herein are approximate, meaning that the term
"about" or "approximately" can be inferred if not expressly
stated.
[0061] The term "molecule" means any distinct or distinguishable
structural unit of matter comprising one or more atoms, and
includes for example polypeptides and polynucleotides.
[0062] As used herein, "cell" means any cell or cells, as well as
viruses or any other particles having a microscopic size, e.g. a
size that is similar to that of a biological cell, and includes any
prokaryotic or eukaryotic cell, e.g., bacteria, fungi, plant and
animal cells. Cells are typically spherical, but can also be
elongated, flattened, deformable and asymmetrical, i.e.,
non-spherical. The size or diameter of a cell typically ranges from
about 0.1 to 120 microns, and typically is from about 1 to 50
microns. A cell may be living or dead. As used herein, a cell is
generally living unless otherwise indicated. As used herein, a cell
may be charged or uncharged. For example, charged beads may be used
to facilitate flow or detection, or as a reporter. Biological
cells, living or dead, may be charged for example by using a
surfactant, such as SDS (sodium dodecyl sulfate). Cell or a
plurality of cells can also comprise cell lines. Example of cell
lines include liver cell, macrophage cell, neuroblastoma cell,
endothelial cell, intestine cell, hybridoma, CHO, fibroblast cell
lines, red blood cells, electrically excitable cells, e.g. Cardiac
cell, myocytes (AT1 cells), cells grown in co-culture, NG108-15
cells (a widely used neuroblastoma X glioma hybrid cell line, ATCC#
HB-12317), primary neurons, a primary cardiac myocyte isolated from
either the ventricles or atria of an animal neonate, an AT-1 atrial
tumor cardiac cell, Liver cells are also known as Hepatocytes,
Secretory cell (depolarize and it secretes things) pancreatic beta
cells secrete insulin, HELA cells (Helen Lane), HEK293 Human
Epithial Kidney c, Erythrocytes (primary red blood cells),
Lymphocytes and the like. Each cell line may include one or more
cells, same or different. For examples, the liver cell comprises at
least one of Human hepatocellular carcinoma ("HEPG2") cell, CCL-13
cell, and H41TE cell, the macrophage cells comprises at least one
of peripheral blood mononuclear cells ("PBMC"), and skin fibroblast
cells, the neuroblastoma cell comprises a U937 cell, the
endothelial cell comprises a human umbilical vein-endothelial cell
("Huv-ec-c"), and the intestine cell comprises a CCL-6 cell.
[0063] "Culture" means a growth of living cells in a controlled
artificial environment. It may be a culture of microorganisms, such
as a bacterial culture, or one of animal or plant cells, such as a
tissue culture. The bioreactors according to the invention can do
both and more. Cultures require appropriate sources of food and
energy, provided by the culture medium, and a suitable physical
environment. Tissue cultures can themselves become a culture medium
for viruses, which grow only with live cells. Cultures of only one
kind of cells are known as pure cultures, as distinguished from
mixed or contaminated cultures.
[0064] "Tissue" means an aggregation of cells more or less similar
morphologically and functionally. The animal body is composed of
four primary tissues, namely, epithelium, connective tissue
(including bone, cartilage, and blood), muscle, and nervous tissue.
The process of differentiation and maturation of tissues is called
histogenesis.
[0065] A "sensor" is broadly defined as any device that can measure
a measurable quantity. For examples, a sensor can be a thermal
detector, an electrical detector, a chemical detector, an optical
detector, an ion detector, a biological detector, a radioisotope
detector, an electrochemical detector, a radiation detector, an
acoustic detector, a magnetic detector, a capacitive detector, a
pressure detector, an ultrasonic detector, an infrared detector, a
microwave motion detector, a radar detector, an electric eye, an
image sensor, any combination of them and the like. A variety of
sensors can be chosen to practice the present invention.
[0066] The term "analyte" means a material that can be consumed or
produced by a cell. Examples of analyte of interest include pH, K,
oxygen, lactate, glucose, ascorbate, serotonin, dopamine, ammonina,
glutamate, purine, calcium, sodium, potassium, NADH, protons,
insulin, NO (nitric oxide) and the like.
[0067] The term "flow" means any movement of fluid such as a liquid
or solid through a device or in a method of the invention, and
encompasses without limitation any fluid stream, and any material
moving with, within or against the stream, whether or not the
material is carried by the stream. For example, the movement of
molecules or cells through a device or in a method of the
invention, e.g. through channels of a substrate on microfluidic
chip of the invention, comprises a flow. This is so, according to
the invention, whether or not the molecules or cells are carried by
a stream of fluid also comprising a flow, or whether the molecules
or cells are caused to move by some other direct or indirect force
or motivation, and whether or not the nature of any motivating
force is known or understood. The application of any force maybe
used to provide a flow, including without limitation, pressure,
capillary action, electroosmosis, electrophoresis,
dielectrophoresis, optical tweezers, and combinations thereof,
without regard for any particular theory or mechanism of action, so
long as molecules or cells are directed for detection, measurement
or sorting according to the invention.
[0068] A "liquid or medium" is a fluid that may contain one or more
substances that affecting growth of cells, one or more analytes, or
any combination of them. A medium can be provided with one or more
analytes to be consumed by one or more cells. A medium can have one
or more analytes generated by one or more cells. A medium can also
have at the same time one or more analytes to be consumed by one or
more cells and one or more analytes generated by one or more cells.
A medium may consist of natural materials, such as enzymatic
digests, extracts of yeast or beef, milk, potato slices, or chick
embryos. Artificial media are prepared by mixing various
ingredients according to particular formulas. A complex medium
contains at least one crude ingredient derived from a natural
material, hence of unknown chemical composition. A chemically
defined or synthetic medium is one in which the chemical structure
and amount of each component are known.
[0069] An "inlet region" is an area of a bioreactor that receives
molecules or cells or liquid. The inlet region may contain an inlet
port and channel, a well or reservoir, an opening, and other
features which facilitate the entry of molecules or cells into the
device. A bioreactor may contain more than one inlet region if
desired. The inlet region is in fluid communication with the
channel and is upstream therefrom.
[0070] An "outlet region" is an area of a bioreactor that collects
or dispenses molecules or cells or liquid. An outlet region is
downstream from a discrimination region, and may contain outlet
channels or ports. A bioreactor may contain more than one outlet
region if desired.
[0071] An "analysis unit" is a microfabricated substrate, e.g., a
microfabricated chip, having at least one inlet region, at least
one channel and chamber, at least one detection region and at least
one outlet region. A device of the invention may comprise a
plurality of analysis units.
[0072] A "channel" is a pathway of a bioreactor of the invention
that permits the flow of molecules or cells to pass a detection
region for detection (identification), or measurement. The
detection and discrimination regions can be placed or fabricated
into the channel. The channel is typically in fluid communication
with an inlet port or inlet region, which permits the flow of
molecules or cells or liquids into the channel. The channel is also
typically in fluid communication with an outlet region or outlet
port, which permits the flow of molecules or cells or liquid out of
the channel. The channel can also be used as a chamber to grown
cells, and vice versa.
[0073] A "detection region" or "sensing volume" or "chamber" is a
location within the bioreactor, typically in or coincident with the
channel (or a portion thereof) and/or in or coincident with a
detection loop, where molecules or cells to be grown, identified,
characterized, hybridized, measured, analyzed or maintained (etc.),
are examined on the basis of a predetermined characteristic. In one
embodiment, molecules or cells are examined one at a time. In other
embodiments, molecules, cells or samples are examined together, for
example in groups, in arrays, in rapid, simultaneous or
contemporaneous serial or parallel arrangements, or by affinity
chromatography.
[0074] "Reaction time" is the time that a system of interest
requires to respond to a change. For example, the reaction time of
a cell is the time required for at least one of the physiological
processes of a cell to adapt or respond to a change in its
environment. Each type of cell has its own characteristic reaction
time with respect to a particular change in its environment. The
reaction time of a sensor is the time required for the sensor to
respond to a change in the quantity that it is sensing. For
example, the reaction time of an electrochemical sensor is set by
the size of the sensor and the thickness and nature of protective
coatings on the activated surfaces of the sensor. The reaction time
of a microfluidic system is determined by, among other things, the
reaction time of the cell to changes in the environment, the time
required for chemical species to diffuse throughout the sensing
volume, the reaction time of the sensor(s) and the diffusion time
of the analyte being controlled by the actuators.
[0075] "Bacteria" are extremely small--usually 0.3-2.0 micrometers
in diameter--and relatively simple microorganisms possessing the
prokaryotic type of cell construction. Each bacterial cell arises
either by division of a preexisting cell with similar
characteristics, or through combination of elements from two such
cells in a sexual process.
[0076] "Protozoa" means a group of eukaryotic microorganisms
traditionally classified in the animal kingdom. Although the name
signifies primitive animals, some Protozoa (phytoflagellates and
slime molds) show enough plantlike characteristics to justify
claims that they are plants. Protozoa range in size from 1 to
10.sup.6 micrometers. Colonies are known in flagellates, ciliates,
and Sarcodina.
[0077] Although marked differentiation of the reproductive and
somatic zooids characterizes certain colonies, such as Volvox,
Protozoa have not developed tissues and organs.
[0078] Several embodiments are now described with reference to the
FIGS. 1-3, in which like numbers indicate like parts throughout the
FIGS. 1-3.
Overview of the Invention
[0079] The inventors of the present invention overcome the
disadvantages of the prior art and develop new bioreactors that
have, among other new and inventive features, the capability of
providing controlled chemokine gradients independent of the
perfusion flow and allow extravasation of a cellular matrix. Recent
advances in the fabrication of nanofilters.sup.57-61 are used to
create perfused-membrane bioreactors according to the present
invention that allow the growth of mixed cultures of cells at
near-to-tissue densities in 1 mm.times.1 mm.times.100 micron
volumes, in the presence of controlled, stable chemokine or
growth-factor gradients within the device, to mimic the in vivo
tumor microenvironment.
[0080] One advantage of the present invention is that custom
devices can be constructed such that the isolated perfusion and
cell-delivery systems allow independent control of shear stress and
chemokine gradients during the course of an experiment. Moreover,
the optical and electrochemical metabolic microsensors can be
installed within these bioreactors to allow simultaneous
quantification of the local metabolic and chemical environment
(lactate, pH, O.sub.2, etc.) in selected regions within the
reactor, while cell migration or cell signaling events are imaged
by fluorescence microscopy. Hence, the bioreactors according to the
present invention can be considered as the next generation of
migration bioreactors that may move beyond a simple MicroTransWell
(MTW) system to one that more closely replicates in vitro the
microenvironment living tissue.
[0081] Moreover, the application of microfabrication techniques,
microfluidics, and microbiosensors with the bioreactors according
to the present invention offers an opportunity for study of the
molecular mechanism of tumor angiogenesis as well as leukocyte and
cancer cell extravasation. For example, the systematic examination
of the role of Tie2 and VEGF in vascular formation and remodeling
and may identify more specific molecular targets for
anti-angiogenic therapy. A similar microdevice model could be used
to examine leukocyte and cancer cell extravasation. These devices
will provide an appropriate cellular environment to host mouse
rumor explants, thereby potentially providing a metastasis assay
for tumor biopsy material. Metabolic sensing in these bioreactors
will help provide a clearer understanding of the tumor
microenvironment and confirm the validity of our in vitro
systems.sup.62-65.
[0082] Additionally, the limitation of the planar Borenstein design
that there is too little surface area of capillaries available to
support the growth of a substantial volume of cells is overcome by
the present invention, which remedies this problem by creating a
multi-layer intercalated supply and return bioreactor that allows
the full surface of a planar bioreactor to be covered with
capillaries, and hence capillary-perfused cells.
[0083] More specifically, in one aspect, the present invention
relates to bioreactors. These bioreactors are
biomicroelectromechanical systems (BioMEMS) that serve as migration
microenvironments to study molecular mechanisms of tumor
angiogenesis, tumor metastasis and leukocyte migration, but can
also function as more general tissue bioreactors and perfusion
systems. Among other things, one unique aspect of these
microfluidic devices is their integration of suitable cell culture
and microfabrication techniques, which permit cell growth in small,
confined, well-perfused volumes at tissue densities, provide
independent control of multiple chemokines and growth factor
gradients, shear forces, tissue perfusion, and permeability of
physical barriers to cellular migration, and allow detailed optical
and electrochemical observation of normal and cancerous cells
during cell migration, intravasation, extravasation, angiogenesis,
and other cellular processes.
[0084] Recent advances in the fabrication of nanofilters.sup.57-61
can be used to practice the present invention to provide
perfused-membrane bioreactors that can allow the growth of mixed
cultures of cells at near-to-tissue densities in 1 mm.times.1
mm.times.100 micron volumes, in the presence of controlled, stable
chemokine or growth-factor gradients within the device, to mimic
the in vivo tumor microenvironment. One advantage of the present
invention is that custom devices can be constructed such that the
isolated perfusion and cell-delivery systems allow independent
control of shear stress and chemokine gradients during the course
of an experiment. Moreover, the optical and electrochemical
metabolic microsensors can be installed within these bioreactors to
allow simultaneous quantification of the local metabolic and
chemical environment (lactate, pH, O.sub.2, etc.) in selected
regions within the reactor, while cell migration or cell signaling
events are imaged by fluorescence microscopy. Hence the next
generation of migration bioreactors will eventually move beyond a
simple MicroTransWell (MTW) system to one that more closely
replicates in vitro the microenvironment living tissue.
[0085] The application of microfabrication techniques,
microfluidics, and microbiosensors offers an opportunity for study
of the molecular mechanism of tumor angiogenesis as well as
leukocyte and cancer cell extravasation. For example, the
systematic examination of the role of Tie2 and VEGF in vascular
formation and remodeling and may identify more specific molecular
targets for anti-angiogenic therapy. A similar microdevice model
could be used to examine leukocyte and cancer cell extravasation.
These bioreactors will provide an appropriate cellular environment
to host mouse tumor explants, thereby potentially providing a
metastasis assay for tumor biopsy material. Metabolic sensing in
these bioreactors will help provide a clearer understanding of the
tumor microenvironment and confirm the validity of our in vitro
systems.sup.62-65.
[0086] Without intent to limit the scope of the invention,
exemplary devices, application of them and related observations
according to the embodiments of the present invention are given
below. Note that titles or subtitles may be used in the examples
for convenience of a reader, which in no way should limit the scope
of the invention. Moreover, certain theories may have been proposed
and disclosed herein; however, in no way they, whether they are
right or wrong, should limit the scope of the invention so long as
the devices and applications of them are practiced according to the
invention without regard for any particular theory or scheme of
action.
Examples
Capillary Bioreactor
[0087] Referring now to FIGS. 1(A-D), the present invention can be
practiced in association with an inventive bioreactor 1100 and its
variants as shown in FIGS. 1(A-D). In one embodiment, referring
first to FIGS. 1A1, 1 A2 and 1 A3, the bioreactor 1100 includes a
first substrate 1124 having a first surface 1124a, an opposite
second surface 1124b and edges. The bioreactor 1100 further
includes a second substrate 1121 having a first surface 1121a and
an opposite second surface 1121b, defining a cavity 1121c with a
bottom surface 1121d, where the bottom surface 1121d is located
therebetween the first surface 1121a and the second surface 1121b.
The first surface 1124a of the first substrate 1124 is received by
the second surface 1121b of the second substrate 1121 to cover the
cavity 1121c so as to form a channel 1101 for receiving cells and a
liquid medium. The second substrate 1121 can be fabricated from
glass, Mylar, PDMS, silicon, a polymer, a semiconductor, or any
combination of them. The first substrate 1124 is at least partially
optically transparent such that the dynamic activities of cells in
the channel 1101 are detectable through optical detecting
means.
[0088] A recess 1105c is formed in the second substrate 1121 with a
bottom surface 1105d and in fluid communication with the channel
1101. Additionally, a barrier 1106 is positioned for covering the
recess 1105c so as to form an outer chamber 1105. The barrier 1006
has a porosity to allow the channel 1101 and the outer chamber 1105
to be in fluid communication and control the move of at least one
predetermined type of cells between the channel 1101 and the outer
chamber 1105.
[0089] In one embodiment as best shown in FIG. 1A1, the barrier
1106 includes a plurality of posts spaced with a gap from each
other. These posts may be coated in certain locations with
substances to prevent entry of cells, particularly the endothelial
cells. Gaps between the posts in certain locations allow for
delivery of particular cell types to the outer chamber 1105
[0090] The second substrate 1121 further defines a first opening
1101a and an opposite, second opening 1101b adapted for allowing a
flow of liquid to be introduced into the channel 1101 through the
first opening 1101a and away from the channel 1101 through the
second opening 1101b substantially along a first direction
1101c.
[0091] The bioreactor 1100 further includes a biocompatible coating
layer 1102 applied to the interior surfaces of the second substrate
1121 around the channel 1101. The biocompatible coating layer 1102
includes a material that may inhibit cell adhesion to the
biocompatible coating layer, enhance cell adhesion to the
biocompatible coating layer, promote organization and growth of
cells, or function as a fluorescent marker or indicator of the
state of cells.
[0092] In forming the bioreactor 1100, the channel 1101 is sized to
allow the growth of a layer of cells 1103 on the biocompatible
coating layer 1102 and the flow of liquid in the channel 1101. The
flow of liquid is controlled so as to provide a known shear force
to the layer of cells 1103. The flow of liquid can be further
controlled so as to provide an environment that simulates a
vascular space in the channel 1101. For examples, the channel 1101
can be used for introduction of endothelial cells, and for their
subsequent perfusion.
[0093] The cells can be any type of living cells, including, but
not limited to, bacteria, protozoa, or both, normal cells,
endothelial cells, tumor cells, or any combination of them. Cells
can be introduced into the channel 1101 individually, in a
collection of cells, or in the form of biofilm. In one embodiment,
the layer of cells 1103 substantially forms an endothelial cells
lined capillary in the channel 1101. The channel 1101 is sized such
that when at least one cell 1104 that is not one of the endothelial
cells, such as a tumor cell, is introduced into the channel 1101,
it can undergo intravasation in the endothelial cells lined
capillary.
[0094] In an alternative embodiment as shown in FIG. 1C, the second
substrate 1121 further defines one or more injection ports 1140,
1141 in fluid communication with the channel 1101 to allow a stream
of substance to be introduced into the channel 1101 through the
injection port 1140, 1141 substantially along a second direction
1148, respectively. As shown in FIG. 1C, the second direction 1148
is substantially perpendicular to the first direction 1101c. The
stream of substance is controlled so as to provide a gradient to
the channel 1101. The stream of substance includes a substance
affecting the growth of cells such as chemokine.
[0095] Referring now to FIGS. 1A1, 1A2 and 1A3, the outer chamber
1105 is sized to allow the growth of a host of cells. The host of
cells includes at least a first type of cells 1107 and a second
type of cells 1113 that is different from the first type of cells
1107. In other words, the outer chamber 1105 is sized to allow the
growth of two types of cells. In one embodiment, the first type of
cells 1107 includes normal cells, and the second type of cells 1113
includes tumor cells. These host cells can either be grown in the
outer chamber 1105, or so as to avoid undesired growth of
endothelial cells into the host cell population, they may be grown
on a suitable substrate outside of the bioreactor 1100 and then be
introduced as a complete unit or smaller units into the outer
chamber 1105 either through one of the microfluid ports or by
temporary removal of the first substrate 1124 such as a glass lid
of the outer chamber 1105. As best shown in FIG. 1A2, a port 1122
and a connection channel 1123 are formed in the second substrate
1121 such that the connection channel 1123 is in fluid
communication with the outer chamber 1105 and the port 1122. The
bioreactor 1100 further includes a plurality of electrodes 1114,
1115, 1116 adapted for electrochemical measurements of the host of
cells. Moreover, the bioreactor 1100 further includes a plurality
of controlling ports 1108, 1109, 1110 and a plurality of connection
channels 1108a, 1109a, 1110a, wherein each of the connection
channels 1108a, 1109a, 1110a is in fluid communication with a
corresponding one of controlling ports 1108, 1109, 1110 and the
outer chamber 1105, respectively.
[0096] Bioreactor 1100 and its variants as given above can find
many applications. Such a readily fabricated device is suitable for
events that are high-probability and in relatively short lengths of
capillary, such as neutrophil binding to a tube of activated
endothelial cells. Multiple channels/ports allow delivery of
different cells, and establishment of chemokine, nutrient, and pH
gradients. Electrodes measure metabolism. Hence it may best suited
for experiments or applications involving activated or inflamed
endothelial cells.
[0097] For example, as shown in FIG. 1B, bioreactor 1100 is used as
a capillary perfused migration bioreactor for the study of cancer
cell or neutrophil extravasation in the presence of two competing
chemokine gradients. In particular, a first stream 1130a of
chemokine is injected through a port 1130 and hence creates a first
gradient of that chemokine both in the outer chamber 1105 and the
channel 1101. Additionally, a second stream 1131a of chemokine is
injected through a port 1131 and hence creates a second gradient of
that chemokine both in the outer chamber 1105 and the channel 1101.
A spectrum of dynamics of the cells may happen. For instances, a
cancer cell or a neutrophil 1132 moves along the channel 1101 in
response to either perfusion flow or the presence of the first and
second chemokine gradients, and a cancer cell or neutrophil 1133
undergoes extravasation from the channel 1101 into the outer
chamber 1105.
[0098] FIG. 1D illustrates another application. Here bioreactor
1100 is used as a capillary perfused migration bioreactor for the
study endothelial tube formation triggered by chemokine excreted by
tumor cells, where the outer chamber 1105 of sufficient size
contain a sufficiently larger volume of host cells 1108 that is
required to ensure endothelial tube formation. An endothelial tube
1140 is formed in response to either chemokine being released by
the tumor cells 1113, or by microfluidic delivery of vascular
endothelial growth factor (VEGF) or other substances through the
microfluidic port 1111. Note that another tumor cell 1112 is on the
move. The electrodes 1114 may be able to detect changes in the
extracellular environment associated with tube formation and the
associated proteolysis.
Bioreactor with Multiple Traps
[0099] Referring now to FIGS. 2(A-I), the present invention can
also be practiced in association with an inventive bioreactor 1000
and its variants as shown in FIGS. 2(A-I). In one embodiment,
referring first to FIGS. 2A, 10B, 10G, 10H and 101, the bioreactor
1000 includes a first substrate 1001 having a first surface 1001a
and an opposite second surface 1001b, defining a chamber 1006
therebetween for receiving cells 1008 and a liquid medium. The
first substrate 1001 can be fabricated from glass, Mylar, PDMS,
silicon, a polymer, a semiconductor, or any combination of
them.
[0100] An inlet port 1021 and a first connection channel 1021a are
formed in the first substrate 1001, where the first connection
channel 1021a is in fluid communication with the inlet port 1021
and the chamber 1006 for allowing a stream of substance to be
delivered to the chamber 1006. Additionally, an outlet port 1005
and a second connection channel 1005a are formed in the first
substrate 1001, where the second connection channel 1005 a is in
fluid communication with the outlet port 1005 and the chamber 1006
for allowing a stream of substance to be removed from the chamber
1006.
[0101] Moreover, as best shown in the insert of FIG. 2 A, the
bioreactor 1000 has confining means 1003 positioned in a region in
the chamber 1006 proximate to the first connection channel 1021a to
confine the cells 1008. In one embodiment, the confining means 1003
includes a plurality of traps 1007, where each of the plurality of
traps 1007 is capable of receiving at least one cell or a
collection of cells 1008. Each of the plurality of traps 1007
includes a structure defining a recess 1007a so as to receive and
confine one or more cells 1008 therein. The structure may be
partially formed with a filter 1007b to allow the recess 1007a to
be in fluid communication with the chamber 1006. The filter 1007b
can be formed with a plurality posts spacing from each other with a
gap g. Traps can take various shapes and have different physics
properties. For examples, in the embodiment as shown in FIG. 2G, a
trap 1090 has distinct posts and sides. In the embodiment as shown
in FIG. 2H, a trap 1092 has posts and sides that are extending to
the posts. And in the embodiment as shown in FIG. 2I, a trap 1093
is formed with a single post and sides. The plurality of traps 1007
can be arranged to form an array.
[0102] Additionally, the first substrate 1001 defines a first
alternate port 1022 and a third connection channel 1022a in fluid
communication with the first alternate port 1022 and the first
connection channel 1021a for allowing additional substance to be
introduced into the chamber 1006. Moreover, the first substrate
1001 further defines a second alternate port 1011, a third
connection channel 1011a, and a second chamber 1009, wherein the
third connection channel 1011a is in fluid communication with
second alternate port 1011 and the second chamber 1009, and the
second chamber 1009 is in fluid communication with the first
connection channel 1021a. Furthermore, the second chamber 1009 is
formed with an oxygen permeable structure to provide oxygen to the
cells.
[0103] Referring now to FIG. 2B, the bioreactor 1100 further
includes a second substrate 1050 having a first surface 1050a and
an opposite, second surface 1050b, and means adapted for
electrochemical measurements of the cells in the chamber 1006. The
means for electrochemical measurements is positioned with the
second substrate 1050 such that when the first surface 1050a of the
second substrate 1050 is received by the second surface 1001b of
the first substrate 1001, the means for electrochemical
measurements is at a corresponding measurement position. The means
for electrochemical measurements includes at least one electrode
1051 monitoring entry of the cells into the chamber 1006, at least
one electrode 1052 monitoring leaving of the cells from the chamber
1006, and a plurality of electrodes 1053 detecting chemical species
in the chamber 1006.
[0104] The bioreactor 1000 further includes a third substrate 1060
having a first surface 1060a and an opposite, second surface 1060b,
and means adapted for optical measurements. The means for optical
measurements is positioned with the third substrate 1060 such that
when the first surface 1060a of the third substrate 1060 is
received by the second surface 1001b of the first substrate 1001,
the means for optical measurements is at a corresponding
measurement position. The means for optical measurements includes a
plurality of optical sensors 1061 strategically positioned for
detecting chemical and biological species within the chamber 1006
and the physiological state of the cells within the chamber 1006.
The third substrate 1060 is at least partially transparent.
Bioreactor with Confined Region
[0105] Referring now to FIGS. 2(C-F), the present invention can
also be practiced in association with an inventive bioreactor 1000
and its variants as shown in FIGS. 2(C-F). In one embodiment,
referring first to FIGS. 2C, 2D, 2E and 2F, the bioreactor 1000
includes a first substrate 1001 having a first surface 1001a and an
opposite second surface 1001b, defining a chamber 1006 therebetween
for receiving cells 1008 and a liquid medium. The first substrate
1001 can be fabricated from glass, Mylar, PDMS, silicon, a polymer,
a semiconductor, or any combination of them. The bioreactor 1000
further includes a second substrate (not shown) sized such that
when the second substrate 1050 received by the first substrate
1001, the chamber 1006 is covered.
[0106] An inlet port (not shown) and a first connection channel
1021a are formed in the first substrate 1001, where the first
connection channel 1021a is in fluid communication with the inlet
port (not shown) and the chamber 1006 for allowing a stream of
substance to be delivered to the chamber 1006.
[0107] Additionally, an outlet port (not shown) and a second
connection channel 1005a are formed in the first substrate 1001,
where the second connection channel 1005a is in fluid communication
with the outlet port (not shown) and the chamber 1006 for allowing
a stream of substance to be removed from the chamber 1006.
[0108] The bioreactor 1000 further has confining means positioned
in the chamber 1006 to form a confinement region 1006a to confine
the cells 1008 therein. In one embodiment, the confining means
includes a first filter 1085a and a second filter 1085b, where the
first filter 1085a is positioned proximate to the first connection
channel 1021 and the second filter 1085b is positioned proximate to
the second connection channel 1005a, and the first filter 1085a and
the second filter 1085b are substantially parallel to each other.
Each of the first filter 1085a and the second filter 1085b includes
a plurality of posts 1086 spaced apart from each other not to allow
cells to pass through it. The distances between two neighboring
posts can vary. For examples, posts 1086, 1086a, 1088 and 1089, as
shown in FIGS. 2C, 2D, 2E and 2F, show them with different gaps,
respectively.
[0109] The first substrate 1001, referring now to FIG. 2C, further
defines a first alternate port 1083 and a third connection channel
1083a that is in fluid communication with the first alternate port
1083 and the confined region 1006a of the chamber 1006 for allowing
seed cells to perfuse only outside the confined region 1006a in the
chamber 1006.
[0110] The bioreactor 1000 further includes one or more supporting
members 1082a, 1082b positioned outside the confined region 1006a
of the chamber 1006 for supporting the second substrate 1050.
Additionally, the bioreactor 1000 further includes at least one
supporting member 1087 positioned inside the confined region 1006a
of the chamber 1006 for supporting the second substrate 1050. Note
that the chamber 1006 is formed with sidewalls of the chamber 1006
are tapered at the intersections of the connection channels with
the chamber 1006 to form an angle of inclination a, which is
preferred in the range of about between 10-45.degree. from
vertical, and an enclosed angle .beta., which is preferred in the
range of about between 30-80.degree., respectively, to avoid shear
forces generated by sharp corners.
Bioreactor with Multiple Chambers
[0111] Referring now to FIGS. 3(A-D), the present invention can
also be practiced in association with an inventive bioreactor 800
and its variants as shown in FIGS. 3(A-D). In one embodiment,
referring first to FIG. 3 A, the bioreactor 800 includes a first
substrate 801 having a first surface and an opposite second
surface, defining a first chamber 812 therebetween for receiving a
first type of cells and a liquid medium. One or more second
chambers 811a, 811b, 811c, 811d are formed in the first substrate
801 for receiving a second type of cells and a liquid medium.
Moreover, one or more connection channels 813a, 813b, 813c, 813d
are formed in the first substrate 801, wherein each of connection
channels 813a, 813b, 813c, 813d is in fluid communication with a
corresponding second chamber 811a, 811b, 811c, 811d and the first
chamber 812 for allowing the first type of cells and the second
type of the cells to interact with each other. For example,
connection channel 813a is in fluid communication with a
corresponding second chamber 811a and the first chamber 812. The
first type of cells includes protozoa, and the second type of cells
includes bacteria.
[0112] The connection channels 813a, 813b, 813c, 813d are formed to
allow protozoa to travel therein. However, a variety of structures
can be utilized to limit the mobility of protozoa for different
applications. For examples, in an embodiment 804 as shown in FIG.
3B, a sizing limiting or exclusion post 805 is utilized to limit
the mobility of protozoa, which can be used to evaluate the
mobility of protozoa. Alternatively, in an embodiment 807 as shown
in FIG. 3C, one of the connection channels 813a, 813b, 813c, 813d
is formed with a cross-sectional dimension 808 variable along the
length of the connection channel is utilized to limit the mobility
of protozoa, which can also be used to evaluate the mobility of
protozoa. Moreover, in an embodiment 809 as shown in FIG. 3D, a
barrier 810 positioned in a connection channel is utilized for
separation of bacteria and protozoa, which can be used to evaluate
protozoa chemotaxis.
[0113] While there has been shown various embodiments of the
present invention, it is to be understood that certain changes can
be made in the form and arrangement of the elements of the
apparatus and steps of the methods to practice the present
invention as would be known to one skilled in the art without
departing from the underlying scope of the invention as is
particularly set forth in the Claims. Furthermore, the embodiments
described above are only intended to illustrate the principles of
the present invention and are not intended to limit the claims to
the disclosed elements. Indeed, since many embodiments of the
invention can be made without departing from the spirit and scope
of the invention, the invention resides in the claims hereinafter
appended.
LIST OF REFERENCES
[0114] 1. Godbey, W. T. and Atala, A., In Vitro Systems for Tissue
Engineering, Ann. N.Y., Acad. Sci, 961, 10-26, 2002. [0115] 2.
Murdin, A. D., Thorpe, J. S., Kirkby, N., Groves, D. J., Spier, R.
E., Immobilisation and Growth of Hybridomas in Packed Beds, In:
Bioreactors and biotransformations, Moody, G. W. and Baker, P. B.,
eds. Elsevier Applied Science Publishers, London, New York, 99-110,
1987. [0116] 3. De Bartolo, L., Jarosch-Von Schweder, G., Haverich,
A., Bader, A., A Novel Full-Scale Flat Membrane Bioreactor
Utilizing Porcine Hepatocytes: Cell Viability and Tissue-Specific
Functions, Biotechnol. Prog., 16, 102-108, 2000. [0117] 4.
McDuffie, N. G., Cell Culture Bioreactors. In: Bioreactor Design
Fundamentals, Butterworth-Heinemann, Boston, 93-119, 1991. [0118]
5. Drioli, E, et al., Biocatalytic Membrane Reactors, Applications
in Biotechnology and the Pharmaceutical Industry, Taylor &
Francis, London, Philadelphia, 1999. [0119] 6. Labecki, M., Bowen,
B. D., Piret, J. M., Protein Transport in Ultrafiltration
Hollow-Fiber Bioreactors for Mammalian Cell Culture, In: Membrane
Separations in Biotechnology, Wang, W. K., ed., M. Dekker, New
York, 1-62, 2001. [0120] 7. Nollert, M. U., Diamond, S. L.,
McIntire, L. V., Hydrodynamic Shear-Stress and Mass-Transport
Modulation of Endothelial-Cell Metabolism, Biotechnol. Bioeng., 38,
588-602, 1991. [0121] 8. Augenstein, D. C., Sinskey, A. J., Wang,
D. I. C., Effect of Shear on Death of Two Strains of Mammalian
Tissue Cells, Biotechnol. Bioeng., 13, 409-418,1971. [0122] 9.
Millward, H. R., Bellhouse, B. J., Sobey, I. J., The Vortex Wave
Membrane Bioreactor: Hydrodynamics and Mass Transfer, Chemical
Engineering Journal and the Biochemical Engineering Journal, 62,
175-181, 1996. [0123] 10. Beeton, S., Bellhouse, B. J., Knowles, C.
J., Millward, H. R., Nicholson, A. M., Wyatt, J. R., A Novel
Membrane Bioreactor for Microbial-Growth, Appl. Microbiol.
Biotechnol., 40, 812-817, 1994. [0124] 11. Hu, W. S. and Aunins, J.
G., Large-Scale Mammalian Cell Culture, Curr. Opin. Biotechnol., 8,
148-153, 1997. [0125] 12. Tobert, W. R., Lewis, C. Jr., White, P.
J., Feder, J., Perfusion Culture Systems for Production of
Mammalian Cell Bio olecules, In: Large-Scale Mammalian cell
culture, Feder, J. and Tolbert, W. R., eds., Academic Press,
Orlando, 97-123, 1985. [0126] 13. Voisard, D., Meuwly, F.,
Ruffieux, P. A., Baer, G., Kadouri, A., Potential of Cell Retention
Techniques for Large-Scale High-Density Perfusion Culture of
Suspended Mammalian Cells, Biotechnol. Bioeng., 82, 751-765, 2003.
[0127] 14. MacNeill, B. D., Pomerantseva, I., Lowe, H. C.,
Oesterle, S. N., Vacanti, J. P., Toward a New Blood Vessel, Vase.
Med., 7, 241-246, 2002. [0128] 15. Wu, H. K., Odom, T. W., Chiu, D.
T., Whitesides, G. M., Fabrication of Complex Three-Dimensional
MicroChannel Systems in PDMS, J. Am. Chem. Soc, 125, 554-559, 2003.
[0129] 16. Griffith, L. G., Emerging Design Principles in
Biomaterials and Scaffolds for Tissue Engineering, Reparative
Medicine: Growing Tissues and Organs, 961, 83-95, 2002. [0130] 17.
Snyder, J. D. and Desai, T. A., Fabrication of Multiple Microscale
Features on Polymer Surfaces for Applications in Tissue
Engineering, Biomedical Microdevices, 3, 293-300, 2001. [0131] 18.
Solan, A., Prabhakar, V., Niklason, L., Engineered Vessels:
Importance of the Extracellular Matrix, Transplant. Proc, 33,
66-68, 2001. [0132] 19. Griffith, L. G. and Naughton, G., Tissue
Engineering--Current Challenges and Expanding Opportunities,
Science, 295, 1009-+, 2002. [0133] 20. Powers, M. J., Domansky, K.,
Kaazempur-Mofrad, M. R., Kalezi, A., Capitano, A., Upadhyaya, A,
Kurzawski, P., Wack, K. E., Stolz, D. B., Kamm, R., Griffith, L.
G., A Microfabricated Array Bioreactor for Perfused 3D Liver
Culture, Biotechnol. Bioeng., 78, 257-269, 2002. [0134] 21. Park,
T. H. and Shuler, M. L, Integration of Cell Culture and
Microfabrication Technology, Biotechnol. Prog., 19, 243-253, 2003.
[0135] 22. Borenstein, J. T., Terai, H., King, K. R., Weinberg, E.
J., Kaazempur-Mofrad, M. R., Vacanti, J. P., Microfabrication
Technology for Vascularized Tissue Engineering, Biomedical
Microdevices, 4, 167-175, 2002. [0136] 23. Kaihara, S., Borenstein,
J., Koka, R., Lalan, S., Ochoa, E. R., Ravens, M., Pien, H.,
Cunningham, B., Vacanti, J. P., Silicon Micromachining to Tissue
Engineer Branched Vascular Channels for Liver Fabrication, Tissue
Eng., 6, 105-117, 2000. [0137] 24. Allen, J. W. and Bhatia, S. N.,
Improving the Next Generation of Bioartificial Liver Devices,
Seminars in Cell & Developmental Biology, 13, 447-454, 2002.
[0138] 25. Passeraub, P. A, Almeida, A. C., Thakor, N. V., Design,
Microfabrication and Analysis of a Microfluidic Chamber for the
Perfusion of Brain Tissue Slices, Biomedical Microdevices, 5,
147-155, 2003. [0139] 26. Fink, C, Ergun, S., Kralisch, D.,
Remmers, U., Weil, J., Eschenhagen, T., Chronic Stretch of
Engineered Heart Tissue Induces Hypertrophy and Functional
Improvement, FASEB J., 14, 669-679, 2000. [0140] 27. Mooney, D. T.,
Mazzoni, C. L., Breuer, C, McNamara, K., Hem, D., Vacanti, J. P.,
Langer, R., Stabilized Polyglycolic Acid Fibre Based Tubes for
Tissue Engineering, Biomaterials, 17, 115-124, 1996. [0141] 28.
Boyden, S., The Chemotactic Effect of Mixtures of Antibody and
Antigen on Polymorphonuclear Leucocytes, J. Exp. Med., 115,
453-466, 1962. [0142] 29. Harvath, L., Falk, W., Leonard, E. J.,
Rapid Quantitation of Neutrophil Chemotaxis--Use of A
Polyvinylpyrrolidone-Free Polycarbonate Membrane in A Multiwell
Assembly, J. Immunol. Methods, 37, 39-45, 1980. [0143] 30. Falk,
W., Goodwin, R. H., Leonard, E. J., A 48-Well Micro Chemotaxis
Assembly for Rapid and Accurate Measurement of Leukocyte Migration,
J. Immunol. Methods, 33, 239-247, 1980. [0144] 31. Yao, J.,
Harvath, L., Gilbert, D. L., Colton, C. A., Chemotaxis by A Cns
Macrophage, the Microglia, J. Neurosci. Res., 27, 36-42, 1990.
[0145] 32. Roth, S. J., Carr, M. W., Rose, S. S., Springer, T. A.,
Characterization of Transendothelial Chemotaxis of T Lymphocytes,
J. Immunol. Methods, 188, 97-116, 1995. [0146] 33. Klemke, R. L.,
Leng, J., Molander, R., Brooks, P. C., Vuori, K., Cheresh, D. A.,
CAS/Crk Coupling Serves As a "Molecular Switch" for Induction of
Cell Migration, Journal of Cell Biology, 140, 961-972, 1998. [0147]
34. Ding, Z., Xiong, K., Issekutz, T. B., Chemokines Stimulate
Human T Lymphocyte Transendothelial Migration to Utilize VLA-4 in
Addition to LFA-1, J. LeukocBiol., 69, 458-466, 2001. [0148] 35.
Jones, D. A., Abbassi, O., Mch tire, L. V., McEver, R. P., Smith,
C. W., P-Selectin Mediates Neutrophil Rolling on
Histamine-Stimulated Endothelial Cells, Biophys. J., 65, 1560-1569,
1993. [0149] 36. Brown, D. and Larson, R., Improvements to Parallel
Plate Flow Chambers to Reduce Reagent and Cellular Requirements,
BMC Immunology, 2, 9-16, 2001. [0150] 37. Cinamon, G. and Alon, R.,
A Real Time in Vitro Assay for Studying Leukocyte Transendothelial
Migration Under Physiological Flow Conditions, J. Immunol. Methods,
273, 53-62, 2003. [0151] 38. Renard, M., Heutte, F.,
Boutherin-Falson, O., Finet, M., Boisseau, M. R., Induced Changes
of Leukocyte Slow Rolling in an in Flow Pharmacological Model of
Adhesion to Endothelial Cells, Biorheology, 40, 173-178, 2003.
[0152] 39. Munn, L. L., Melder, R. J., Jain, R. K., Analysis of
Cell Flux in the Parallel-Plate Flow Chamber--Implications for Cell
Capture Studies, Biophys. J., 67, 889-895, 1994. [0153] 40. Ley,
K., The Selectins As Rolling Receptors, hi: The selectins:
initiators of leukocyte endothelial adhesion, Vestweber, D, ed.
Harwood Academic Publishers, Australia, 63-104, 1997. [0154] 41.
Papadaki, M. and McIntire, L. V., Quantitative Measurement of
Shear-Stress Effects on Endothelial Cells. In: Tissue engineering
methods and protocols, Morgan, J. R. and Yarmush, M. L, eds. Humana
Press, Totowa, N.J., 577-593, 1999. [0155] 42. Ramos, C. L. and
Lawrence, M. B., Quantitative Measurement of Cell-Cell Adhesion
Under Flow Conditions, In: Tissue engineering methods and
protocols, Morgan, J. R. and Yarmush, M. L., eds. Humana Press,
Totowa, N.J., 507-519, 1999. [0156] 43. Hammer, D. A. and Brunk, D.
K., Measuring Receptor-Mediated Cell Adhesion Under Flow Cell-Free
Systems, hi: Tissue engineering methods and protocols, Morgan, J.
R. and Yarmush, M. L., eds. Humana Press, Totowa, N.J., 543-552,
1999. [0157] 44. Jain, R. K., Munn, L. L., Fukumura, D., Melder, R.
J., In Vitro and In Vivo Quantification of Adhesion Between
Leukocytes and Vascular Endothelium. In: Tissue engineering methods
and protocols, Morgan, J. R. and Yarmush, M. L., eds. Humana Press,
Totowa, N.J., 553-575, 1999. [0158] 45. Li, C. Y., Shan, S., Huang,
Q., Braun, R. D., Lanzen, J., Hu, K., Lin, P., Dewhirst, M. W.,
Initial Stages of Tumor Cell-Induced Angiogenesis: Evaluation Via
Skin Window Chambers in Rodent Models, J Natl Cancer lost, 92,
143-7, 2000. [0159] 46. Jain, R. K., Munn, L. L., Fukumura, D.,
Dissecting Tumour Pathophysiology Using Intravital Microscopy. Nat.
Rev Cancer, 2, 266-76, 2002. [0160] 47. Jain, R. K., Munn, L. L,
Fukumura, D., Dissecting Tumour Pathophysiology Using Intravital
Microscopy. Nature Reviews Cancer, 2, 266-276, 2002. [0161] 48.
Jain, R. K., Angiogenesis and Lymphangiogenesis in Tumors: Insights
From Intravital Microscopy, Cold Spring Harb. Symp. Quant. Biol.,
67, 239-248, 2002. [0162] 49. Folkman, J., Bach, M., Rowe, J. W.,
Davidoff, F., Lambert, P., Hirsch, C, Goldberg, A., Hiatt, H. H.,
Glass, J., Henshaw, E., Tumor Angiogenesis--Therapeutic
Implications, N. Engl. J. Med., 285, 1182-1186, 1971. [0163] 50.
Weidner, N., Semple, J. P., Welch, W. R., Folkman, J., Tumor
Angiogenesis and Metastasis--Correlation in Invasive
Breast-Carcinoma, N. Engl. J. Med., 324, 1-8, 1991. [0164] 51. Lin,
P., Buxton, J. A, Acheson, A, Radziejewski, C, Maisonpierre, P. C.,
Yancopoulos, G. D., Channon, K. M., Hale, L. P., Dewhirst, M. W.,
George, S. E., Peters, K. G., Antiangiogenic Gene Therapy Targeting
the Endothelium-Specific Receptor Tyrosine Kinase Tie2, Proc. Natl.
Acad Sci USA, 95, 8829-34, 1998. [0165] 52. Lin, P., Polverini, P.,
Dewhirst, M., Shan, S., Rao, P. S., Peters, K., Inhibition of Tumor
Angiogenesis Using a Soluble Receptor Establishes a Role for Tie2,
in Pathologic Vascular Growth, J Clin Invest, 100, 2072-8, 1997.
[0166] 53. Lin, P., Sankar, S., Shan, S., Dewhirst, M. W.,
Polverini, P. J., Quinn, T. Q., Peters, K. G., Inhibition of Tumor
Growth by Targeting Tumor Endothelium Using a Soluble Vascular
Endothelial Growth Factor Receptor, Cell Growth Differ, 9, 49-58,
1998. [0167] 54. Heidemann, J., Ogawa, H., Dwinell, M. B., Rafiee,
P., Maaser, C, Gockel, H. R., Otterson, M. F., Ota, D. M.,
Lugering, N., Domschke, W., Binion, D. G., Angiogenic Effects of
friterleukin 8 (CXCL8) in Human Intestinal Microvascular
Endothelial Cells Are Mediated by CXCR2, J. Biol. Chem., 278,
8508-8515, 2003. [0168] 55. Li, Y., Tondravi, M., Liu, J., Smith,
E., Haudenschild, C. C., Kaczmarek, M., Zhan, X., Cortactin
Potentiates Bone Metastasis of Breast Cancer Cells, Cancer Res, 61,
6906-11, 2001. [0169] 56. Higgs, H. N. and Pollard, T. D.,
Regulation of Actin Filament Network Formation Through Arp2/3
Complex: Activation by a Diverse Array of Proteins, Annu Rev.
Biochem., 70, 649-676, 2001. [0170] 57. Li, F. Y., Zhang, L.,
Metzger, R. M., On the Growth of Highly Ordered Pores in Anodized
Aluminum Oxide, Chem. Mater., 10, 2470-2480, 1998. [0171] 58. Li,
A. P., Muller, F., Bimer, A., Nielsch, K., Gosele, U., Hexagonal
Pore Arrays With a 50-420 Nm friterpore Distance Formed by
Self-Organization in Anodic Alumina, J. Appl. Phys., 84, 6023-6026,
1998. [0172] 59. Black, C. T., Guarini, K. W., Milkove, K. R.,
Baker, S. M., Russell, T. P., Tuominen, M. T., Integration of
Self-Assembled Diblock Copolymers for Semiconductor Capacitor
Fabrication, Appl. Phys. Lett, 79, 409-411, 2001. [0173] 60. Black,
C. T. and Guarini, K. W., Diblock Copolymers: Self-Assembly for
Applications in Microelectronics, In: Encyclopedia of Materials:
Science and Technology, Buschow, K H J, ed. Elsevier, New York,
1-6, 2002. [0174] 61. Guarini, K. W., Black, C. T., Zhang, Y., Kim,
H., Sikorski, E. M., Babich, I N., Process Integration of
Self-Assembled Polymer Templates into Silicon Nanofabrication,
Journal of Vacuum Science & Technology B, 20, 2788-2792, 2002.
[0175] 62. MartinezZaguilan, R, Seftor, E. A., Seftor, R. E. B.,
Chu, Y. W., Gillies, R. J., Hendrix, M. J. C., Acidic PH Enhances
the Invasive Behavior of Human Melanoma Cells, Clinical &
Experimental Metastasis, 14, 176-186, 1996. [0176] 63. Gillies, R.
J., Raghunand, N., Karczmar, G. S., Bhujwalla, Z. M., MRI of the
Tumor Microenvironment, J. Magn. Reson. Imaging, 16, 430-450, 2002.
[0177] 64. Bhujwalla, Z. M., Artemov, D., Ballesteros, P., Cerdan,
S..sub.5 Gillies, R. J., Solaiyappan, M, Combined Vascular and
Extracellular PH Imaging of Solid Tumors, NMR Biomed., 15, 114-119,
2002. [0178] 65. Helmlinger, G., Schell, A., Dellian, M., Forbes,
N. S., Jain, R. K., Acid Production in Glycolysis-Impaired Tumors
Provides New Insights into Tumor Metabolism, Clin. Cancer Res., 8,
1284-1291, 2002.
* * * * *